From laboratory studies to clinical trials: Temozolomide use in idh‐mutant gliomas

Abstract

In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH‐mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH‐mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ.